ALK-Abello, S.A.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Copenhagen Denmark (1923)

Organization Overview

First Clinical Trial
1996
NCT00135642
First Marketed Drug
1930
meadow fescue grass pollen allergen
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ALK ABELLO | ALK-Abelló | ALK - Abello A/S | ALK-Abello A/S | ALK-Abelló A/S | ALK-Abelló A/S, Boege Alle 6-8, 2970 Hoersholm, Denmark | ALK-Abello, Inc. | ALK Nordic A/S, Danmark Filial | ALK-SCHERAX Arzneimittel GmbH | Allergy Laboratories, Inc. | Center Laboratories, Inc. | Clinical Research Director, ALK-Abelló, S.A.

Active Ingredients

Marketed Drugs (19)

Key: ALK-Abello, S.A. (18) Acquired (1)

bee venom (1991)

bermuda grass pollen allergen (1930)

cat epidermis allergen (1930)

ciprofloxacin (cipro) (2015)

histamine (1950)

house dust mite allergen (1930)

kentucky bluegrass pollen allergen (1930)

lolium perenne pollen (1930)

meadow fescue grass pollen allergen (1930)

mixed vespid venom protein (1991)

orchard grass pollen allergen (1930)

redtop grass pollen allergen (1930)

short ragweed pollen allergen (1930)

sweet vernal grass pollen allergen (1930)

timothy grass pollen allergen extract (Grastek) (1930)

wasp venom protein (1991)

white faced hornet venom protein (1991)

yellow hornet venom protein (1991)

yellow jacket venom protein (1991)

Drugs in Phase 4 Trials (8)

albuterol (proventil) (4 trials)

ambrosia pollen (1 trial)

betula (1 trial)

epinephrine (levophed) (1 trial)

grazax (9 trials)

house dust mite allergen (12 trials)

short ragweed pollen allergen (4 trials)

sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair) (1 trial)

Drugs in Phase 3 Trials (16)

Key: ALK-Abello, S.A. (14) Acquired (2)

acetaminophen (tylenol) (3 trials)

birch allergen (2 trials)

budesonide (rhinocort) (1 trial)

desloratadine (clarinex) (2 trials)

fluticasone (cutivate) (2 trials)

formoterol (foradil) (1 trial)

loratadine (claritin) (2 trials)

mometasone (elocon) (2 trials)

olive allergen (1 trial)

olopatadine (patanol) (2 trials)

pangramin (1 trial)

prednisone (meticorten) (3 trials)

succinylcholine (anectine) (6 trials)

timothy grass pollen allergen extract (Grastek) (7 trials)

tree allergen (2 trials)

trifolium pratense (10 trials)

Drugs in Phase 2 Trials (9)

avanz salsola (1 trial)

cat epidermis allergen (1 trial)

cs02 (1 trial)

cupressus arizonica (1 trial)

dupilumab (dupixent) (1 trial)

metformin (glucophage) (1 trial)

oak tree allergen (1 trial)

osiris (1 trial)

verapamil (calan) (1 trial)

Drugs in Phase 1 Trials (3)

acetylcysteine (mucomyst) (1 trial)

betula verrucosa allergen extract (1 trial)

peanut allergen (Palforzia) (1 trial)

Drugs in Other Trials (2)

alutard (1 trial)

dog hair extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 4)

Cluster Headache (Phase 2)

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 2)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Eczema (Phase 3)

Headache (Phase 2)

Hypersensitivity (Phase 3)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial APIs: 38